EYP001a Food Effect Study in Subjects With Chronic Hepatitis B Virus (HBV) Infection
Status:
Completed
Trial end date:
2017-10-12
Target enrollment:
Participant gender:
Summary
The farnesoid X receptor (FXR) regulates hepatitis B virus replication through the bile acids
pathway. EYP001a is a selective, synthetic FXR agonist under development for the treatment of
hepatitis B.
This Phase 1 study is designed primarily to assess Pharmacokinetics (PK) under fed and fasted
conditions, and to assess the safety, tolerability and Pharmacodynamics (PD) of single oral
doses of EYP001a in subjects with chronic HBV infection.